Abbott Laboratories (ABT) EPS Estimated At $0.65

September 17, 2017 - By Henry Gaston

 Abbott Laboratories (ABT) EPS Estimated At $0.65
Investors sentiment increased to 1.01 in Q4 2016. Its up 0.05, from 0.96 in 2016Q3. It improved, as 83 investors sold Abbott Laboratories shares while 496 reduced holdings. 103 funds opened positions while 481 raised stakes. 1.06 billion shares or 1.63% more from 1.04 billion shares in 2016Q3 were reported.
Moreover, Ashfield Ltd Liability Co has 0.43% invested in Abbott Laboratories (NYSE:ABT). Nj State Employees Deferred Compensation Plan holds 10,000 shares. Michigan-based State Treasurer State Of Michigan has invested 0.16% in Abbott Laboratories (NYSE:ABT). Pictet Savings Bank And Trust Ltd invested in 1.21% or 93,420 shares. Fincl Bank Of The West holds 0.15% or 29,132 shares. California-based Eqis Mgmt has invested 0.03% in Abbott Laboratories (NYSE:ABT). Rand Wealth Lc reported 56,075 shares. Capital Glob Invsts holds 7.51 million shares or 0.09% of its portfolio. Cs Mckee Ltd Partnership holds 1.39% or 473,268 shares in its portfolio. Peddock Advsrs Ltd Liability Company has invested 0.07% in Abbott Laboratories (NYSE:ABT). Horan Advsrs Ltd Co holds 1.34% or 46,752 shares. Concert Wealth Mgmt stated it has 22,263 shares or 0.19% of all its holdings. Vaughan David Inc Il has invested 0.97% in Abbott Laboratories (NYSE:ABT). Parkside National Bank, a Missouri-based fund reported 11,469 shares. Davis R M Inc invested in 0.07% or 39,209 shares.

Since March 31, 2017, it had 0 buys, and 2 sales for $60,722 activity. 767 shares were sold by Contreras Jaime, worth $34,240. 552 shares were sold by Watkin Jared, worth $26,482 on Thursday, June 15.

Investors wait Abbott Laboratories (NYSE:ABT) to report on October, 18. its quarterly earnings Wall Street analysts expect $0.65 EPS, up $0.06 or 10.17 % from last year’s $0.59 same quarter earnings. This translates into $1.13 billion profit for ABT giving the stock a 19.91 P/E. This is assuming the current $0.65 EPS is accurate. Abbott Laboratories’s Wall Street analysts see 4.84 % EPS growth, taking into account the $0.62 EPS reproted in the previous quarter, The stock increased 0.12% or $0.06 on September 15, reaching $51.76. About 6.70M shares traded or 45.02% up from the average. Abbott Laboratories (NYSE:ABT) has risen 15.90% since September 17, 2016 and is uptrending. It has underperformed by 0.80% the S&P500.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 23 analysts covering Abbott Laboratories (NYSE:ABT), 14 have Buy rating, 0 Sell and 9 Hold. Therefore 61% are positive. Abbott Laboratories had 70 analyst reports since July 24, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $48 target in Tuesday, September 13 report. Jefferies maintained Abbott Laboratories (NYSE:ABT) on Tuesday, June 14 with “Buy” rating. William Blair downgraded Abbott Laboratories (NYSE:ABT) on Friday, January 29 to “Market Perform” rating. The rating was maintained by BMO Capital Markets on Thursday, August 31 with “Hold”. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Wednesday, April 19 by Stifel Nicolaus. On Thursday, August 17 the stock rating was initiated by Citigroup with “Hold”. As per Friday, June 16, the company rating was maintained by Jefferies. The stock has “Neutral” rating by UBS on Tuesday, September 22. As per Monday, June 26, the company rating was maintained by RBC Capital Markets. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, January 29.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The company has market cap of $89.93 billion. The Firm operates through four divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. It has a 79.47 P/E ratio. The Company’s Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Reuters.com which released: “BRIEF-Abbott Laboratories says ‍NHS Business Services Authority approved …” on September 13, 2017, also Nasdaq.com with their article: “Why Is Abbott Laboratories (ABT) Down 3.1% Since the Last Earnings Report?” published on August 21, 2017, Thestreet.com published: “Alibaba, Qorvo, Abbott Laboratories, Square: ‘Mad Money’ Lightning Round” on September 16, 2017. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Investorplace.com and their article: “3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and …” published on September 12, 2017 as well as Chicagotribune.com‘s news article titled: “Abbott releases software fixes for heart devices that could be hacked” with publication date: August 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.